{"id":"vehicle-of-ophthalmic-loteprednol-etabonate","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased intraocular pressure"}]},"_chembl":{"chemblId":"CHEMBL1200865","moleculeType":"Small molecule","molecularWeight":"466.96"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It does this by binding to the glucocorticoid receptor, which then inhibits the transcription of pro-inflammatory genes. This leads to a decrease in the production of prostaglandins, which are mediators of inflammation.","oneSentence":"Loteprednol etabonate is a corticosteroid that reduces inflammation by inhibiting the production of prostaglandins.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:22.525Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of inflammation and pain associated with ocular surgery"}]},"trialDetails":[{"nctId":"NCT05322148","phase":"PHASE3","title":"Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization","status":"COMPLETED","sponsor":"Research Insight LLC","startDate":"2022-06-03","conditions":"Dry Eye","enrollment":59},{"nctId":"NCT02813265","phase":"PHASE3","title":"Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Kala Pharmaceuticals, Inc.","startDate":"2016-06","conditions":"Dry Eye Syndromes, Keratoconjunctivitis Sicca","enrollment":918},{"nctId":"NCT02163824","phase":"PHASE3","title":"Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation","status":"COMPLETED","sponsor":"Kala Pharmaceuticals, Inc.","startDate":"2014-05","conditions":"Ocular Infections, Irritations and Inflammations","enrollment":380},{"nctId":"NCT02218489","phase":"PHASE2","title":"Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease","status":"COMPLETED","sponsor":"Kala Pharmaceuticals, Inc.","startDate":"2014-07","conditions":"Blepharitis","enrollment":206},{"nctId":"NCT02786901","phase":"PHASE3","title":"LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2016-06","conditions":"Cataract, Pain, Ocular Inflammation","enrollment":600},{"nctId":"NCT02188160","phase":"PHASE2","title":"Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Kala Pharmaceuticals, Inc.","startDate":"2014-06","conditions":"Dry Eye Syndromes, Keratoconjunctivitis Sicca","enrollment":150},{"nctId":"NCT02819284","phase":"PHASE3","title":"Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Kala Pharmaceuticals, Inc.","startDate":"2016-06","conditions":"Dry Eye Syndromes, Keratoconjunctivitis Sicca","enrollment":909},{"nctId":"NCT02793817","phase":"PHASE3","title":"Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain","status":"COMPLETED","sponsor":"Kala Pharmaceuticals, Inc.","startDate":"2016-06","conditions":"Post Surgical Ocular Inflammation and Pain","enrollment":520},{"nctId":"NCT02208297","phase":"PHASE3","title":"Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2014-09","conditions":"Inflammation, Pain, Cataract","enrollment":326},{"nctId":"NCT01996839","phase":"PHASE3","title":"Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2013-12","conditions":"Inflammation, Pain, Cataract","enrollment":514},{"nctId":"NCT01749241","phase":"NA","title":"Efficacy of Loteprednol Ointment Following Eyelid Surgery","status":"WITHDRAWN","sponsor":"University of California, San Diego","startDate":"2012-09","conditions":"Post-operative Healing Following Blepharoplasty and Ptosis Repair","enrollment":""},{"nctId":"NCT00699153","phase":"PHASE3","title":"Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2008-06","conditions":"Ocular Inflammation","enrollment":400},{"nctId":"NCT00645671","phase":"PHASE3","title":"Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2008-03","conditions":"Ocular Inflammation","enrollment":400},{"nctId":"NCT00705159","phase":"PHASE4","title":"Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2008-06","conditions":"Conjunctivitis","enrollment":137},{"nctId":"NCT01107405","phase":"PHASE2","title":"Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2010-04","conditions":"Allergic Conjunctivitis","enrollment":101},{"nctId":"NCT01060072","phase":"PHASE3","title":"Evaluation of Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2010-02","conditions":"Inflammation, Pain","enrollment":407},{"nctId":"NCT01010633","phase":"PHASE3","title":"Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2009-11","conditions":"Inflammation, Pain","enrollment":406},{"nctId":"NCT00420628","phase":"PHASE4","title":"Pediatric Zylet Safety and Efficacy Study","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2006-11","conditions":"Chalazion, Hordeolum","enrollment":108},{"nctId":"NCT00560638","phase":"PHASE2","title":"Loteprednol Etabonate Opthalmic Suspension for the Treatment of Dry Eye","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2005-11","conditions":"Dry Eye","enrollment":119}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":29,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Vehicle of Ophthalmic Loteprednol Etabonate","genericName":"Vehicle of Ophthalmic Loteprednol Etabonate","companyName":"Bausch & Lomb Incorporated","companyId":"bausch-lomb-incorporated","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Loteprednol etabonate is a corticosteroid that reduces inflammation by inhibiting the production of prostaglandins. Used for Treatment of inflammation and pain associated with ocular surgery.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}